ATRC · AtriCure, Inc.
$35.04
+6.37% last session
End-of-day data · updated 2026-07-28
Market cap
$2B
Enterprise value
$2B
Trailing P/E
178.0
Forward P/E
86.3
Dividend yield
—
Beta
1.25
Avg volume
1M
Employees
1K
2D change
—
5D change
13.24%
10D change
6.92%
30D change
23.82%
60D change
35.06%
MTD change
25.70%
YTD change
-5.54%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ATRC
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-28
Latest call per bank · past 12 months
UBS
Buy$50.00
+42.7% vs priceJP Morgan
Overweight$48.00
+37.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-28 | UBS | Maintains | Buy | $55.00 → $50.00 |
| 2026-05-06 | Canaccord Genuity | Maintains | Buy | $53.00 → $55.00 |
| 2026-02-18 | Canaccord Genuity | Maintains | Buy | $64.00 → $53.00 |
| 2026-02-18 | UBS | Maintains | Buy | $60.00 → $55.00 |
| 2026-02-18 | Citizens | Maintains | Market Outperform | $60.00 → $52.00 |
| 2026-02-18 | Oppenheimer | Downgrade | Outperform → Perform | $0.00 |
| 2026-02-18 | BTIG | Reiterates | Buy | $54.00 |
| 2026-02-12 | Needham | Reiterates | Buy | $45.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 75 — overbought territory; the recent run-up may be due for a pause.
- Price vs 50-day MA: Trading 31.4% above the 50-day MA ($30.24).
- Price vs 200-day MA: Trading 20.2% above the 200-day MA ($33.08).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is positive (+0.28) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($25.86) and high ($42.41).
ATRC Price Chart
Loading chart for ATRC…
Fundamentals
About AtriCure, Inc.
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
More in Medical Instruments & Supplies
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.